Cancer progression is not driven solely by tumour cells but also by their surrounding immune environment.

A new study reveals that migration and invasion inhibitory protein (MIIP) acts as a crucial regulator that restrains colorectal cancer development by preventing immune cells from adopting tumour-supportive behaviours.

Researchers discovered that MIIP suppresses the polarisation of macrophages into the pro-tumour M2 state through a signalling cascade involving STING, NFκB2, and IL-10.

By interrupting this immune feedback loop, MIIP reduces cancer cell migration, invasion, and metastasis.

The findings uncover an unexpected mechanism linking chromosomal instability, immune signalling, and tumour progression, offering new insights into how manipulating the tumour microenvironment may improve therapeutic strategies for colorectal cancer.

Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, largely due to metastasis and limited responses to immunotherapy in most patients.

Although immune checkpoint inhibitors have transformed treatment for certain tumour subtypes, the majority of colorectal cancers remain "immune-cold," meaning they fail to trigger effective anti-tumour immunity.

Increasing evidence suggests that tumour-associated macrophages, especially the M2 subtype, actively promote tumour growth, invasion, and immune suppression.

However, the molecular signals that drive macrophage polarisation within colorectal tumours remain poorly understood.

Understanding how tumour cells reshape immune behaviour is therefore essential for improving therapy outcomes.

Based on these challenges, deeper investigation into tumour–immune communication mechanisms became necessary.

Researchers from Tianjin Medical University Cancer Institute & Hospital and collaborating institutions in Cancer Biology & Medicine that migration and invasion inhibitory protein (MIIP) suppresses colorectal cancer progression by regulating immune signalling within the tumour microenvironment.

Through multi-omics analysis, cell experiments, and animal models, the team demonstrated that MIIP blocks M2 macrophage polarisation via the STING–NFκB2–IL10 signalling axis.

Their findings reveal how tumour cells and immune cells form a feedback loop that drives metastasis and identify a potential therapeutic target for patients who respond poorly to existing immunotherapies.

The researchers combined bioinformatics analyses, cellular experiments, co-culture systems, and mouse models to uncover MIIP's immunological role.

Analysis of patient datasets showed that low MIIP expression correlated with activation of STING signalling, increased infiltration of M2 macrophages, and poorer clinical outcomes.

Laboratory experiments confirmed that reducing MIIP levels increased cytoplasmic DNA stress signals, triggering STING activation and downstream NFκB2 signalling.

This signalling cascade enhanced production of IL-10, an immunosuppressive cytokine known to drive macrophages toward the tumour-promoting M2 phenotype.

In co-culture experiments, macrophages exposed to MIIP-deficient cancer cells displayed elevated M2 markers and secreted higher IL-10 levels.

These macrophages, in turn, significantly increased cancer cell migration and invasion—demonstrating a self-reinforcing immune feedback loop.

Animal studies further validated the mechanism: tumours expressing higher MIIP levels showed reduced growth, fewer liver metastases, and diminished M2 macrophage infiltration.

Importantly, blocking STING signalling reversed tumour-promoting effects caused by MIIP loss, highlighting the pathway's therapeutic relevance.

Clinical tissue analyses confirmed negative correlations between MIIP expression and STING, IL-10, and macrophage infiltration, linking the molecular mechanism directly to patient prognosis.

According to the study authors, the findings redefine MIIP as more than a tumour suppressor acting inside cancer cells.

Instead, MIIP serves as a regulator of immune communication within tumours.

By controlling macrophage polarisation, MIIP determines whether the tumour microenvironment becomes hostile or supportive to cancer growth.

The researchers emphasise that targeting immune signalling pathways rather than tumour cells alone may represent a promising direction for future therapies, particularly for patients whose tumours do not respond to current immune checkpoint treatments.

The discovery opens new possibilities for precision immunotherapy in colorectal cancer.

Measuring MIIP expression could help identify patients likely to benefit from therapies targeting the STING pathway or macrophage-mediated immune suppression.

Pharmacological inhibition of STING signalling showed therapeutic potential in experimental models, suggesting a strategy for transforming immune-resistant tumours into treatment-responsive ones.

Beyond colorectal cancer, the study highlights a broader principle: tumour progression can be controlled by reshaping immune cell behaviour rather than directly killing cancer cells.

Future therapies may therefore combine immune microenvironment modulation with existing treatments to reduce metastasis and improve long-term survival outcomes.

Source: China Anti-Cancer Association